FDA Policy May Shift to Single Pivotal Trial for Drug Approvals
A potential FDA policy shift is being discussed that would make one pivotal clinical trial the default requirement for drug approvals. This change could lower costs and accelerate timelines for smaller biotech companies, but it would also increase the risk associated with a single trial's failure.
- The traditional requirement for two large-scale clinical trials has been the standard since the 1960s to ensure that a drug's positive results are reproducible and not due to chance. - While this policy shift makes a single trial the new "default," the FDA has had the legal authority to approve drugs based on one trial plus other "confirmatory evidence" since 1997. - In recent years, single-trial approvals have become increasingly common, especially for drugs treating cancer and rare diseases; in 2024, 66% of all new drugs were approved based on a single pivotal trial. - Proponents of the change, including FDA Commissioner Marty Makary, argue that modern trial designs and a better understanding of biology can make a single, high-quality study more effective than two less rigorous ones, potentially saving companies $30 million to $150 million per trial. - This change will likely have a bigger impact on treatments for common conditions in areas like cardiology or psychiatry, as oncology and rare disease drugs have often been granted approval based on a single trial already. - Critics raise concerns that relying on a single trial increases the risk of approving a drug based on a "false positive" result, pointing to past instances where drugs like the cancer treatment Bevacizumab were approved on limited data and later found to be ineffective in follow-up studies. - The move brings the U.S. regulatory approach closer to that of European agencies, which have frequently accepted single compelling trials for drug approval. - To complement this faster approval path, the FDA plans to enhance its "postmarket initiative," which involves collecting robust real-world data on a drug's performance and safety after it has been approved and is in use by the public.
